BRPI1016189A2 - ccr2 antagonist 4-azetidinyl-1-phenyl-cyclohexane compounds - Google Patents
ccr2 antagonist 4-azetidinyl-1-phenyl-cyclohexane compoundsInfo
- Publication number
- BRPI1016189A2 BRPI1016189A2 BRPI1016189A BRPI1016189A BRPI1016189A2 BR PI1016189 A2 BRPI1016189 A2 BR PI1016189A2 BR PI1016189 A BRPI1016189 A BR PI1016189A BR PI1016189 A BRPI1016189 A BR PI1016189A BR PI1016189 A2 BRPI1016189 A2 BR PI1016189A2
- Authority
- BR
- Brazil
- Prior art keywords
- azetidinyl
- phenyl
- ccr2 antagonist
- cyclohexane compounds
- cyclohexane
- Prior art date
Links
- VOBLMJKUYJTNEK-UHFFFAOYSA-N 1-(4-phenylcyclohexyl)azetidine Chemical class C1CCN1C1CCC(C=2C=CC=CC=2)CC1 VOBLMJKUYJTNEK-UHFFFAOYSA-N 0.000 title 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17030709P | 2009-04-17 | 2009-04-17 | |
| PCT/US2010/031265 WO2010121046A1 (en) | 2009-04-17 | 2010-04-15 | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016189A2 true BRPI1016189A2 (en) | 2016-04-19 |
Family
ID=42167720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016189A BRPI1016189A2 (en) | 2009-04-17 | 2010-04-15 | ccr2 antagonist 4-azetidinyl-1-phenyl-cyclohexane compounds |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100267689A1 (en) |
| EP (1) | EP2419419B1 (en) |
| JP (1) | JP5675773B2 (en) |
| KR (1) | KR20120006544A (en) |
| CN (1) | CN102459227B (en) |
| AR (1) | AR076328A1 (en) |
| AU (1) | AU2010236346B2 (en) |
| BR (1) | BRPI1016189A2 (en) |
| CA (1) | CA2758934A1 (en) |
| ES (1) | ES2528625T3 (en) |
| MX (1) | MX2011010964A (en) |
| NZ (1) | NZ595432A (en) |
| TW (1) | TW201102377A (en) |
| WO (1) | WO2010121046A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018997B1 (en) | 2008-12-10 | 2013-12-30 | Янссен Фармацевтика Нв | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| AU2010236393B2 (en) * | 2009-04-16 | 2014-11-13 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 |
| ES2541607T3 (en) | 2009-04-17 | 2015-07-22 | Janssen Pharmaceutica Nv | CCR2 antagonists of cyclohexane bound to 4-azetidinyl-1-heteroatom |
| WO2010121046A1 (en) | 2009-04-17 | 2010-10-21 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| TW201211027A (en) * | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| KR101743280B1 (en) | 2010-06-17 | 2017-06-02 | 얀센 파마슈티카 엔.브이. | Cyclohexyl-azetidinyl antagonists of ccr2 |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| BR112014012056B1 (en) | 2011-11-18 | 2021-12-14 | Heptares Therapeutics Limited | MUSCARINE M1 RECEPTOR AGONIST COMPOUNDS, A PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS AND USE THEREOF TO TREAT A COGNITIVE OR PSYCHOTIC DISORDER OR TO TREAT OR REDUCE THE SEVERITY OF ACUTE, CHRONIC, NEUROPATHIC OR INFLAMMATORY PAIN |
| PT2785710T (en) * | 2011-12-01 | 2017-12-18 | Chemocentryx Inc | Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists |
| EP2862856B1 (en) | 2012-06-15 | 2018-08-01 | Mitsubishi Tanabe Pharma Corporation | Imidazole and triazole compounds as dgat-1 inhibitors |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| RS61013B1 (en) | 2014-10-24 | 2020-11-30 | Landos Biopharma Inc | Lanthionine synthetase c-like 2-based therapeutics |
| ES2764840T3 (en) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Use of plerixafor to treat and / or prevent acute exacerbations of chronic obstructive pulmonary disease |
| MA42133A (en) | 2015-05-21 | 2021-06-02 | Chemocentryx Inc | CCR2 MODULATORS |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| BR112020005284A2 (en) | 2017-09-25 | 2020-09-24 | Chemocentryx, Inc. | combination therapy using a chemokine 2 receptor antagonist (ccr2) and a pd-1 / pd-l1 inhibitor |
| CA3083442A1 (en) | 2017-11-30 | 2019-06-06 | Landos Biopharma, Inc. | Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| IL275898B2 (en) | 2018-01-08 | 2025-05-01 | Chemocentryx Inc | Methods of treating solid tumors with ccr2 antagonists |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110028395A (en) * | 2019-05-29 | 2019-07-19 | 宁夏中星显示材料有限公司 | A kind of preparation method of 4- (4- hydroxy phenyl) cyclohexanone |
| CA3135502C (en) | 2019-12-20 | 2024-01-09 | Josep Bassaganya-Riera | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2293408A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| AU4796700A (en) * | 1999-05-13 | 2000-12-05 | Dupont Pharmaceuticals Research Laboratories, Inc. | Ureido-substituted cyclic amine derivatives and their use as drug |
| CN1192773C (en) | 1999-08-04 | 2005-03-16 | 帝人株式会社 | Cyclic amine CCR3 antagonisis |
| CA2390531A1 (en) | 1999-11-08 | 2001-05-17 | Wyeth | ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders |
| US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| CA2432369A1 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Pharma Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1377625B1 (en) * | 2001-03-26 | 2006-06-14 | Bayer MaterialScience AG | Polycarbonate having a pronounced shear thinning behavior |
| CN1741994A (en) * | 2002-11-27 | 2006-03-01 | 因塞特公司 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| KR100895968B1 (en) * | 2002-11-27 | 2009-05-07 | 인사이트 코포레이션 | 3-Aminopyrrolidine derivatives as modulators of chemokine receptors |
| EP1696919B1 (en) | 2003-12-18 | 2013-10-02 | Incyte Corporation | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| KR20070063562A (en) * | 2004-09-28 | 2007-06-19 | 얀센 파마슈티카 엔.브이. | Substituted Dipiperidine CCR2 Antagonists |
| PA8653301A1 (en) * | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | SALTS OF THE N- [2 - ({(3R) -1- [TRANS-4-HIDROXI-4- (6-METOXIPIRIDIN-3-IL) CICLOHEXIL) PIRROLIDIN |
| GB0513747D0 (en) | 2005-07-06 | 2005-08-10 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| US20070197590A1 (en) | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| CL2007002958A1 (en) * | 2006-10-12 | 2008-05-09 | Epix Delaware Inc | COMPOUNDS DERIVED FROM HETEROARIL-CARBOXAMIDA, ANTAGONISTS OF THE CHEMIOQUINE RECEPTOR; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF SUCH DISEASES AS REJECTION OF ORGAN TRANSPLANTS, Rheumatoid Arthritis, LUPUS, ENTR |
| JP2011506466A (en) * | 2007-12-11 | 2011-03-03 | 株式会社サイトパスファインダー | Carboxamide compounds and their use as chemokine receptor agonists |
| EA018997B1 (en) * | 2008-12-10 | 2013-12-30 | Янссен Фармацевтика Нв | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| AU2010236393B2 (en) * | 2009-04-16 | 2014-11-13 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 |
| WO2010121046A1 (en) | 2009-04-17 | 2010-10-21 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| ES2541607T3 (en) * | 2009-04-17 | 2015-07-22 | Janssen Pharmaceutica Nv | CCR2 antagonists of cyclohexane bound to 4-azetidinyl-1-heteroatom |
-
2010
- 2010-04-15 WO PCT/US2010/031265 patent/WO2010121046A1/en not_active Ceased
- 2010-04-15 CN CN201080027641.6A patent/CN102459227B/en not_active Expired - Fee Related
- 2010-04-15 BR BRPI1016189A patent/BRPI1016189A2/en not_active Application Discontinuation
- 2010-04-15 KR KR1020117026846A patent/KR20120006544A/en not_active Withdrawn
- 2010-04-15 NZ NZ595432A patent/NZ595432A/en not_active IP Right Cessation
- 2010-04-15 JP JP2012506232A patent/JP5675773B2/en not_active Expired - Fee Related
- 2010-04-15 ES ES10714804.1T patent/ES2528625T3/en active Active
- 2010-04-15 EP EP10714804.1A patent/EP2419419B1/en active Active
- 2010-04-15 US US12/761,080 patent/US20100267689A1/en not_active Abandoned
- 2010-04-15 MX MX2011010964A patent/MX2011010964A/en active IP Right Grant
- 2010-04-15 AU AU2010236346A patent/AU2010236346B2/en not_active Ceased
- 2010-04-15 CA CA2758934A patent/CA2758934A1/en not_active Abandoned
- 2010-04-16 TW TW099111898A patent/TW201102377A/en unknown
- 2010-04-19 AR ARP100101287A patent/AR076328A1/en unknown
-
2011
- 2011-10-25 US US13/280,690 patent/US8513229B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010236346A1 (en) | 2011-11-03 |
| CN102459227A (en) | 2012-05-16 |
| US20120040960A1 (en) | 2012-02-16 |
| NZ595432A (en) | 2013-12-20 |
| WO2010121046A1 (en) | 2010-10-21 |
| CA2758934A1 (en) | 2010-10-21 |
| KR20120006544A (en) | 2012-01-18 |
| MX2011010964A (en) | 2011-11-02 |
| JP2012524111A (en) | 2012-10-11 |
| US8513229B2 (en) | 2013-08-20 |
| AU2010236346B2 (en) | 2015-01-22 |
| US20100267689A1 (en) | 2010-10-21 |
| EP2419419B1 (en) | 2014-12-03 |
| CN102459227B (en) | 2014-08-20 |
| TW201102377A (en) | 2011-01-16 |
| EP2419419A1 (en) | 2012-02-22 |
| ES2528625T3 (en) | 2015-02-11 |
| JP5675773B2 (en) | 2015-02-25 |
| AR076328A1 (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016189A2 (en) | ccr2 antagonist 4-azetidinyl-1-phenyl-cyclohexane compounds | |
| BRPI1013614A2 (en) | substituted spiro-amide compounds | |
| CY2017026I2 (en) | QUATRACYCLIC COMPOUND | |
| SMT201600008B (en) | PIRIDAZINONE COMPOUNDS | |
| SMT201600351B (en) | ANTIVIRAL COMPOUNDS | |
| DK2427449T3 (en) | VINYLINDAZOLYL COMPOUNDS | |
| BR112012006859A2 (en) | compounds | |
| BRPI1005525A2 (en) | azaazulene compounds | |
| BRPI1008774A2 (en) | substituted spiroamide | |
| BR112012005616A2 (en) | heterocyclic antiviral compounds | |
| BRPI1010852A2 (en) | heterocyclic antiviral compounds | |
| BRPI1013868A2 (en) | diacylethylenediamine compound | |
| HRP20150167T1 (en) | COMPOUNDS AS BRADIKININ-B1 ANTAGONISTS | |
| BRPI0810926A2 (en) | CRIG ANTAGONIST | |
| UY33156A (en) | NEW TIENOPIRROL COMPOUNDS | |
| IT1401535B1 (en) | TOOL | |
| BRPI1016266A2 (en) | heterocyclic antiviral compounds | |
| BR112012002336A2 (en) | azaheterocyclic compounds | |
| BRPI0923237A2 (en) | ccr2 antagonist 4-azetidinyl-1-heteroaryl cyclohexanol compounds | |
| EP2503066A4 (en) | CONSTRUCTION MACHINE | |
| DK2427454T3 (en) | Heterocyclic phenoxymethyl compounds | |
| BRPI1016207A2 (en) | ccr2 antagonists 4-azetidinyl-1-heteroaryl cyclohexane compounds | |
| BRPI1007369A2 (en) | dihydroquinolinone derivatives | |
| FR2952847B3 (en) | > | |
| EP2448583A4 (en) | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |